What is ELAB's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ELAB.

Stock Ratings / Health Care / ELAB / options

SBFM (27) REVB (36) PPBT (49) PPCB (32) ⌘ Pro Terminal →

PMGC Holdings Inc. (ELAB) Options Positioning, Max Pain & Unusual Sweeps

$2.10 -19.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.02

PMGC Holdings Inc. (ELAB) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ELAB Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ELAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, PMGC Holdings Inc. (NASDAQ: ELAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $2.10 (-19.23% 1D, market cap $2.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ELAB ranks #897 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ELAB compare to SBFM and REVB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELAB carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 31.4%, and ROIC of -35.0%. By comparison, SBFM (Sunshine Biopharma Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -21.4%, cap $2.2M) and REVB (Revelation Biosciences Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M). Among the 5-stock peer group, ELAB leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ELAB?

▼

Per ELAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840563), PMGC Holdings Inc. generated $590.1K in revenue (-84.4% YoY), -$7.7M in net income, and -$6.4M in free cash flow against $12.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.02 (-3.65%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELAB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (27/100 Composite)

🔍 WHY ELAB SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 18.5% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.96-5.1% Next Q

Q2 (-2Q)

Grade E$2.81-8.2% Next Q

Q3 (-1Q)

Grade E$2.58-18.6% Next Q

Current

Grade E$2.10-10.3% Hist 90D α

Trajectory: E (35) → E (27)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ELAB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ELAB currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.89) and Max Pain ($2.21) forces dealer call-delta covering toward $1,566.43.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELAB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ELAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 27%NO 73%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ELAB)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ELAB.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELAB)

✓Walkthrough of ELAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ELAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -90.99%⚡ TESTING RESISTANCE

2026-11-03O $2.64H $2.64L $2.10C $2.10VOL 7.5K

RES: $3.30SUP: $-2.89SMA50: $3.89SMA200: $33.50

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ELAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ELAB Butterfly Map → + Track ELAB →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -84.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ELAB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ELAB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ELAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELAB)

Health Care Rank #897 of 1015 ⚔️ SBFM vs ELAB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ELAB vs. SBFM, REVB, PPBT, PPCB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, PMGC Holdings Inc. (ELAB) ranks #897 by composite RQD confidence (27/100, grade E) and #993 by equity capitalization ($2.1M). Within this direct 5-issuer industry benchmark cohort, ELAB leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. PPBT currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with ELAB at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ELAB ACTIVE PMGC Holdings Inc.	E	27/100	—	31.4%	-35.0%	-19.23%	$2.1M	Benchmark Subject
SBFM Sunshine Biopharma Inc.	E	27/100	—	33.8%	-21.4%	-6.14%	$2.2M	/sbfm-vs-elab →
REVB Revelation Biosciences Inc.	D-	36/100	—	—	-35.0%	+0.50%	$2.3M	/revb-vs-elab →
PPBT Purple Biotech Ltd.	D	49/100	—	—	—	+5.13%	$1.9M	/ppbt-vs-elab →
PPCB Propanc Biopharma Inc.	E	32/100	—	—	-35.0%	-6.52%	$1.9M	/ppcb-vs-elab →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001840563 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PMGC Holdings Inc. (ELAB) reported GAAP revenue of $590.1K (-84.4% vs. FY2024 revenue of $3.8M , and -65.5% cumulative change since FY2023) , GAAP net income of -$7.7M, operating cash flow of -$5.9M, and free cash flow of -$6.4M (-16.0% YoY). On the balance sheet, ELAB closed FY2025 with $12.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$590.1K	-$7.7M	-$5.9M	-$6.4M	$12.9M	—
FY2024 (FY)	2024-12-31	$3.8M	-$6.2M	-$5.5M	-$5.5M	$9.0M	—
FY2023 (FY)	2023-12-31	$1.7M	-$4.3M	-$4.6M	-$4.6M	—	—

3. ELAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ELAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ELAB compare to SBFM and REVB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ELAB?

Where is ELAB trading relative to its 50-day, 200-day, and 52-week technical levels?

ELAB last traded at $2.10 (-19.23% on volume of 12,757,896 shares), positioning the stock -46.02% below its 50-day simple moving average ($3.89) and -93.73% below its 200-day simple moving average ($33.50). Across its 52-week range of $2.51 to $1,491.84, ELAB sits at the 0.0% percentile with a 14-day RSI of 27.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.84 to $2.36).

Direct Sub-Reports: ELAB RQD Cockpit ELAB 12M Forecast ELAB Earnings & Move ELAB Dividends & DRIP ELAB Insiders & 13F ELAB Whale Options ELAB Profit Sankey ELAB News & Why

ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ SEC XBRL & RQD VERIFIED

ELAB — PMGC Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

PMGC Holdings Inc. (ELAB) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.10 (-19.23% 1D, market capitalization $2.1M).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 31.4%, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

PMGC Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the financials section, the company reported revenue of $0.6M in FY 2025 and $1.7M in FY 2023, with — reported for FY 2024.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), PMGC Holdings Inc. (ELAB) reported $590.1K in annual revenue (up from $3.8M in FY2024, -84.4% YoY) and -$7.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.7M revenue, -$4.3M net income) through FY2025, ELAB scaled operating cash flow to -$5.9M and free cash flow to -$6.4M, backed by $12.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.51 – $1,491.84 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— the supply_chain field is NONE and the butterfly_links and proprietary_signals arrays are empty, so the source data identifies no upstream or downstream dependencies, sector correlation links, or second-order bottlenecks.

Key Question #1: Can ELAB sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $590.1K and free cash flow of -$6.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is ELAB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ELAB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PMGC Holdings Inc. (ELAB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ELAB Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 21h ago

PMGC Holdings Inc. Announces DBA as NorthStrive Holdings, Inc., Trademark License Agreement, and Website Update

Yahoo Finance report covering PMGC Holdings Inc. (ELAB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Drone prototype work is underway at PMGC Holdings (ELAB) under an exclusive university license.

Stock Titan report covering PMGC Holdings Inc. (ELAB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

PMGC Holdings Details Acquisition Platform and Maritime Defense Technology Plans

TradingView report covering PMGC Holdings Inc. (ELAB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Timothy Sykes • 1d ago

ELAB Rebrands As NorthStrive, Drawing Fresh Trader Focus

Timothy Sykes report covering PMGC Holdings Inc. (ELAB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

PMGC Holdings (ELAB) Trades at $3.04, Up 2.36% as Shares Test Upper Range - Composite Profile

https://www.siam.in/ report covering PMGC Holdings Inc. (ELAB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Australia • 1d ago

Northstrive Acquisition Corp I. (NSAI) stock price, news, quote and history

Yahoo Finance Australia report covering PMGC Holdings Inc. (ELAB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 1d ago

NorthStrive Acquisition Corp I Announces Business Combination with Nuclea Energy

The proposed business combination values Nuclea Energy at an enterprise value of $350 million, subject to adjustments at closingThe transaction is expected to close in the first half of 2027Nuclea is developing advanced

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ELAB Bull vs. Bear Conversation Board — What's Your Call at $2.10?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ELAB 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $3.38 (+30.0%)

📌 Pinned Debate

The balance-sheet pillar is the strongest component at 8/20 with an Altman Z-Score of 2.5 and Debt/Equity of 0.5, and the stock traded

Here is why I am bullish on ELAB here at $2.60: The balance-sheet pillar is the strongest component at 8/20 with an Altman Z-Score of 2.5 and Debt/Equity of 0.5, and the stock traded up 2.72% in the latest session.. Compare ELAB's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $2.47 are getting bought.

EarningsSniper 🐂 BULL

@SkepticalCFA Shorting a 3/20 institutional whale-flow stock at $2.60 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $1.95 (-25.0%)

Spot @ $2.60

Negative ROIC of -35%, zero FCF yield, and a Piotroski F-Score of 3/9 combine with a Roarable Strong Sell verdict and net losses in eve

I respect the product at PMGC Holdings Inc., but the stock at $2.60 is a different story. Negative ROIC of -35%, zero FCF yield, and a Piotroski F-Score of 3/9 combine with a Roarable Strong Sell verdict and net losses in every reported period.. FCF yield is 0.0% and RQD sits at 27/100 (E) — why pay up here when you can wait for next quarter's numbers?